<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Scientific Research on Drug Regulation]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[监管科学背景下的药品管理战略研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:16</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[赵培培<sup>1,2</sup>，毛振宾<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵培培<sup>1,2</sup>，毛振宾<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408007&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[国内外电子药品说明书使用和监管分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2024/9/11 10:05:16</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[刘宏明<sup>1</sup>，曹森<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘宏明<sup>1</sup>，曹森<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202408008&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the implementation status and countermeasures of drug marketing authorization holder system in china]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The Marketing Authorization Holder (MAH) system is the core and basic system throughout the Drug Administration Law of the People's Republic of China. To further leverage the role of the MAH system in optimizing resource allocation and implementing the primary responsibility of holders, institutional documents since the implementation of the MAH system in China has been summarized and organized. Based on the actual situation of China's pharmaceutical industry and its regulation, as well as drawing on international experience, targeted improvement suggestions are proposed. Such as strengthening the holders to perform their duties responsibly, exploring the establishment of a unified and independent cross-provincial regulatory mechanism and a third regulator, and improving the laws and regulations of the MAH system.]]></description>
<pubDate>2024/6/11 10:53:52</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[GAN Changjiao, CHEN Li, YUAN Yanfang, FANG Jun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>GAN Changjiao, CHEN Li, YUAN Yanfang, FANG Jun</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405007&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Overview and progress of international standards for rubber pharmaceutical packaging materials]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  Rubber pharmaceutical packaging materials are essential components in drug packaging. This paper aims to investigate and analyze the overview of international standards for rubber pharmaceutical packaging materials, providing insights for the establishment and optimization of China's national standards system for rubber pharmaceutical packaging materials.<b>Methods</b>  Through a systematic review of the standard systems for rubber pharmaceutical packaging materials in various national pharmacopeias and industry standards, the standards for rubber in international standards such as the United States Pharmacopeia and the European Pharmacopoeia are discussed and analyzed.A comparative analysis is conducted to examine the interconnections and differences among these standards.<b>Results</b>  This study summarizes the standard formats, key points in quality control, and the latest developments in different rubber pharmaceutical packaging materials standards. <b>Conclusion</b>  Considering the characteristics and forms of international standards for rubber pharmaceutical packaging materials, recommendations are proposed based on the requirements for correlated assessments and the construction of national standards systems. These suggestions aim to contribute to the development and enhancement of China's pharmaceutical packaging materials standards, aligning with industry growth and regulatory demands.]]></description>
<pubDate>2024/6/11 10:53:52</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[JIA Feifei, ZHAO Xia, YANG Huiying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>JIA Feifei, ZHAO Xia, YANG Huiying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202405008&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion of the development status, trend and enlightenment of organoids and organ-on-chips from the perspective of regulatory science of cosmetics]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In recent years, new complex in vitro models such as organoids and organ-on-chips have emerged at the forefront of international technology and research, gradually being applied to drug and cosmetic research, development, and supervision while attracting considerable attention. This article first briefly explains the basic concepts, development history, and technical characteristics of organoids and organ-on-chips. It then provides examples of their application in safety and efficacy testing of cosmetic ingredients. Finally, combining domestic and international cosmetic regulations, it looks forward to future trends using organoids and organ-on-chips to improve the efficiency of cosmetic ingredient research and support regulatory decision-making. Additionally, it proposes regulatory suggestions for the application of this type of new technology from a perspective of regulatory science with an aim to provide technical reserves for cosmetic regulation that aligns with China's situation and promote the transformation of innovative achievements in scientific research into practical regulatory tools.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[LIN Ni, ZHANG Fenglan, YU Zhenxi, WANG Gangli, LU Yong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIN Ni, ZHANG Fenglan, YU Zhenxi, WANG Gangli, LU Yong</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404008&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Preliminary study on the application of digital medical supervision principle in software as a medical device in China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The development of emerging technologies has promoted the popularity of digital therapy, and software has become an important part of medical products. Software as a Medical Device (SaMD) with the functions of diagnosis, prevention and treatment, as a subset of medical device software, also belongs to the category of digital medical care. However, due to the lack of a complete and comprehensive evaluation and supervision system at home and abroad, it is urgent to strengthen supervision research on its supervision. This paper introduces the related concepts and policies of SaMD, the regulatory challenges faced by SaMD under the background of artificial intelligence, and the management principles of digital medical care in China and WHO, so as to inform readers of the ideas for strengthening the review and supervision of SaMD, with a view to providing enlightenment for improving the regulatory principles of SaMD in China.]]></description>
<pubDate>2024/5/20 16:36:51</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[WANG Ying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Ying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202404009&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of development trends in overseas produced of chemical drugs in China from the perspective of registration and inspection testing]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide reference for the policy formulation of drug regulatory agencies and the R&D and production of domestic drug manufacturers.<b>Methods</b>  Combing and counting the data of registration inspection of overseas produced of chemical drugs in China from 2015 to 2023, we analyze the changes, reasons and development trend of the information of the number of registration inspections, varieties, indications, production countries, and agents in the territory from the perspectives of APIs and preparations, combined with the issuance of complementary inspections.<b>Results</b>  The number of registration inspection of overseas produced of chemical drugs showed a trend of first decrease and then increase with 2018 as the inflection point.The number and proportion of APIs and preparations issued with supplementary inspection increased year by year from 2020, and the most items issued with supplementary inspection were related substances.<b>Conclusion</b>  The adjustment of regulatory policies has a significant impact on the amount of registered tests of APIs, which in turn affects the total amount of registered tests.Domestic manufacturers could differentiate their competition from multiple perspectives such as innovation and encouraging imitation.Regulatory authorities could further strengthen the post-marketing regulation and verification supervision of overseas produced of chemical drugs to ensure the safety of the quality.Registration applicants could establish perfect quality standards by combining domestic and foreign guidelines, and agents could continuously strengthen policy learning, improve the quality of registration and inspection materials, and guarantee the timeliness of registration and inspection.]]></description>
<pubDate>2025/9/17 10:50:06</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[LI Wenlong, YAO Shangchen, ZHANG Yu, WU Chaoyang, WEI Jingjing, HUANG Haiwei, SUN Huimin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI Wenlong, YAO Shangchen, ZHANG Yu, WU Chaoyang, WEI Jingjing, HUANG Haiwei, SUN Huimin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508007&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Exploration and reflection on the implementation strategy of remote supervision in the production process of medical device manufacturers in the context of the artificial intelligence]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[AI-enabled remote supervision of production processes represents a critical pathway for the government's innovative regulatory models, strengthening digital government construction, and achieving intelligent supervision. Addressing the pain points of traditional on-site inspections in the medical device industry—such as geographical, spatial, and resource constraints—this paper focuses on how to effectively implement remote supervision of production processes within this sector in the era of artificial intelligence. By analyzing the current state and challenges of industry supervision, and drawing on practical remote supervision experience from diverse fields both domestically and internationally, as well as the application outcomes of AI, this study aims to explore and propose remote supervision methods and implementation strategies tailored to the characteristics of the medical device industry.]]></description>
<pubDate>2025/9/17 10:50:06</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[LIU Qi<sup>1</sup>, MA Chao<sup>2</sup>, SU Xiaohui<sup>1</sup>, XU Hui<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Qi<sup>1</sup>, MA Chao<sup>2</sup>, SU Xiaohui<sup>1</sup>, XU Hui<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202508008&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the path of new quality productivity to promote high quality development of pharmaceutical regulation]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[General Secretary Xi Jinping's series of important expositions and major deployments on new quality productivity have provided a basic guideline for the high-quality development of Drug regulation. This paper focuses on the development path of new quality productivity in China's drug regulation. At present, China's drug innovation in some tracks has realized the change from running behind to running in parallel, and the renewal of the structure of the pharmaceutical industry has accelerated, hence the characteristics of the new quality productivity of the drug regulatory object are gradually unfolding. The main factors driving the new quality productivity of drug regulation are laborers and labor tools, and that means the  regulatory personnel and regulatory tools. Existing problems include a large shortage of high-quality regulatory personnel; traditional regulatory tools are difficult to meet the demand; and a smart regulatory model has not yet been fully established. Accordingly, specific measures are proposed to cultivate innovative talents in regulatory science in the new era, accelerate the innovation of drug regulatory tools and promote the innovation of drug regulatory models, with a view to accelerating the development of new quality productivity in drug regulation and contributing to the high-quality development of drug regulation.]]></description>
<pubDate>2025/3/12 11:34:39</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[YUAN Yanfang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUAN Yanfang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502008&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and reflection on the policy of centralized volume procurement for traditional Chinese medicine formula granules]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Traditional Chinese medicine (TCM) formula granules offer therapeutic effects comparable to TCM decoction pieces, while also providing the advantages of easy preparation and convenience in use, which has led to high recognition among doctors and patients. With the dissemination and popularization of TCM, the overall number of outpatient prescriptions for TCM formula granules is on an upward trend, and the industry scale is continuously expanding. The implementation of the national policy for the routine and institutionalized centralized volume procurement of drugs, along with the expansion policy and the improvement of TCM formula granules management policies, has made centralized procurement of TCM formula granules a trend. However, the centralized volume procurement of TCM formula granules faces numerous challenges in the implementation process, including quality control, supply chain management, and the mechanism for price formation. This paper aims to review and analyze the relevant policies, procurement status, and issues of TCM formula granules, and based on research literature, to propose corresponding suggestions, in the hope of providing a reference for the centralized volume procurement of TCM formula granules.]]></description>
<pubDate>2025/3/12 11:34:39</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[ZHANG Shen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Shen</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202502009&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on strategies for balancing authority and communication reach in government new media for drug regulation: A case study of ＂Chinese Pharmaceutical News＂]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Ever since the new era started, China has made significant progress in the development of government new media for drug regulation. These platforms continue to face a structural dilemma in which authority and communication reach are often difficult to reconcile. This kind of tension fundamentally limits the sustainable growth of government new media in the drug regulation area. In response to this challenge, government new media brands for drug regulation, represented by ＂Chinese Pharmaceutical News＂, have developed a three-dimensional communication system featuring differentiated platform deployment, hierarchical system-wide coordination, and audience-oriented integrated communication. This system has effectively integrated administrative and social resources, expanded the dissemination of authoritative information, and enabled the precise delivery of science popularization content. It offers a practical pathway for resolving the tension between authority and communication reach and provides useful experience for improving the effectiveness of pharmaceutical regulatory communication.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[ZHANG Yu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Yu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609008&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Practice on improving biological product testing capability in Yunnan＇s biomedicine development]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609009&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To provide a reference for provincial drug testing institutions to enhance their biological product testing capabilities. <b>Methods</b>  This paper  based on the development of Yunnan Province＇s biopharmaceutical industry, analyzes the new requirements for drug testing capabilities and supervision brought by industrial upgrading. It systematically details the construction path and optimization suggestions across personnel, equipment, samples, quality systems, environment, and biosafety, drawing on the Yunnan Institute of Supervision and Inspection for Food and Drug＇s practice in building testing capabilities centered on vaccine batch release from 2019 to 2025. <b>Results and Conclusion</b>  Through measures like a ＂variety + equipment＂ dual-responsible person system, the Yunnan Institute quickly established a comprehensive testing system covering major product categories, using batch release capacity as a breakthrough.. This has strongly supported local supervision and industrial innovation. Its experience indicates that demand orientation, a project-driven approach, policy support, and sustained investment form an effective path for provincial drug testing institutions to address gaps and support high-quality industry development.]]></description>
<pubDate>2026/10/19 8:53:41</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[WANG Sijie, LIU Qin, HE Wenzhi, SHEN Xue, YANG Huan, WU Fan, FEI Chengrui]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Sijie, LIU Qin, HE Wenzhi, SHEN Xue, YANG Huan, WU Fan, FEI Chengrui</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202609009&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the characteristics and optimization path of regulatory scientific research in the field of cell gene therapy in China]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601007&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Regulatory science research drives high-level studies and efficient translation in China's pharmaceutical regulatory science through innovations in regulatory tools, standards, and methodologies. Regulatory agencies play a crucial role in this process. This paper focused on the field of cell and gene therapy,analyzing articles published by relevant national pharmaceutical regulatory institutions to explore the curent regulatory science research ecosystem in China and the role of regulatary agencies within this domain. Based on these findings, we propose optimization suggestions to promote the development of regulatory science research,enhance pharmaceutical regulatory capabilities and accelerate the market entry of innovative products.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[SUN Tanlin]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Tanlin</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601007&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The R&D strategy analysis for Mongolian medicines under the new Chinese medicine registration policy]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601008&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This manuscript aims to discuss the opportunities and the development challenges of Mongolian medicines under the background of the new policies for traditional Chinese medicine registration and proposes the path of modernization and development. It analyzes the application of network pharmacology and other technologies in the research and development (R&D) of innovative Mongolian medicines and the construction of the “computation-experimentation-clinical” holistic model. It discusses the balance between developing new Mongolian herbs and protecting the environment. It elaborates on policy support for developing classic prescriptions and establishing quality standards. It points out that Mongolian medicines with the same name need to draw on Chinese medicine's experience to avoid low-level duplication. The new Mongolian medicines R&D should be guided by policies. It should fully seize opportunities such as the registration of classic formulas and the development of improved new drugs, and adhere to the equal importance of inheritance and innovation. Ultimately, achieve the sustainable development goals of modernization and internationalization through the in-depth integration of multidisciplinary technologies and the efficient synergy of the whole industrial chain.]]></description>
<pubDate>2026/2/24 15:15:08</pubDate>
<category><![CDATA[Scientific Research on Drug Regulation]]></category>
<author><![CDATA[YUE Siyu<sup>1,2</sup>, QI Xiao<sup>1</sup>, LIANG Guodong<sup>1,3</sup>, GA Lu<sup>1</sup>, GAO Xin<sup>1</sup>, BU Ren<sup>1</sup>, ZHAO Dongming<sup>1</sup>, MA Yuheng<sup>1</sup>, LIU Bin<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YUE Siyu<sup>1,2</sup>, QI Xiao<sup>1</sup>, LIANG Guodong<sup>1,3</sup>, GA Lu<sup>1</sup>, GAO Xin<sup>1</sup>, BU Ren<sup>1</sup>, ZHAO Dongming<sup>1</sup>, MA Yuheng<sup>1</sup>, LIU Bin<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202601008&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>